Organofluorine chemistry:
science, technologies, manufacture since 1987
12 April 2017
Pentafluorophenol production

The launch of new production on the basis of the technology developed by P&M-Invest is one of the main activities of our company.Within the framework of an establishment of Joint Venture between the Chinese company Qi-Chem and P&M-Invest at the present time there is Pentafluorophenol's technology development by the representatives of the company Qi-Chem the subsequent production of this product at factory in China. Learning new technologies developed by P&M-Invest is going on at the experimental site near Moscow.

Pentafluorophenol is the main starting material for the production of the drug Sofosbuvir, which is widely used for the treatment of hepatitis C worldwide. Due to the fact that the market consumption of this product is growing rapidly, the need for medical drug is large.

17 February 2017
Negotiations between Qi-Chem and P&M-Invest, had resulted in the signing of an agreement to establish a joint venture.

Negotiations, held on February 14-17 between Qi-Chem and P&M-Invest, had resulted in the signing of an agreement to establish a joint venture.

The registration of joint venture is scheduled for April, 2017.

.


9 February 2017
Attention! All scientists, students & PhD candidates!

P&M-Invest offers “products from stock” as free samples (not more then 3 substances) in the quantity 5-20g, subject to the publication of their results, obtained based on each sample, in our journal “Fluorine notes” within 6 months. The promotion is valid within 2017.

Note: The delivery of free of samples is paid by receiver.

22 October 2016
P&M-Invest took part in international pharmaceutical exhibition CPhI Worldwide
P&M-Invest took part in international pharmaceutical exhibition CPhI Worldwide, which was held in Barcelona on 4 -5 of October
27 June 2016
New compounds are now available, catalog numbers from 2027 to 2039